N A Dyachenko

Regional Medical Clinic Hospital of Emergency Medical Care named after N.S. Karpovich, Krasnoyarsk, Russia.

1 publication 2025 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does N A Dyachenko research?

N A Dyachenko studies the effectiveness of Revelise, a medication used for treating ischemic strokes, which occur when blood flow to a part of the brain is blocked. By analyzing data from large groups of stroke patients, Dyachenko aims to understand how well this medication helps patients recover and regain their abilities after experiencing a stroke. The research highlights treatment outcomes, especially in older adults and those with additional health conditions, showcasing practical results that can inform medical practices for stroke care.

Key findings

  • In the study involving 2,202 patients, nearly half (49.9%) had good outcomes at discharge.
  • After 90 days, the percentage of patients with good outcomes improved to 66.4%.
  • Revelise significantly reduces stroke-related disabilities, even in older patients.

Frequently asked questions

Does Dr. Dyachenko study treatments for ischemic stroke?
Yes, Dr. Dyachenko specifically researches the medication Revelise for treating ischemic strokes.
What is Revelise, and how does it help stroke patients?
Revelise is a medication that helps restore blood flow to the brain during a stroke, aiding in recovery and reducing disabilities.
Who benefits from Dr. Dyachenko's research?
Patients suffering from ischemic strokes and their healthcare providers benefit from the findings as they can lead to better treatment decisions.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.